{"slideshow_credits": null, "snippet": "The genetic analysis services provider Illumina said Roche's $5.7 billion takeover offer was \"grossly inadequate\" and that the Swiss drug maker's director candidates should be rejected.", "abstract": "The genetic analysis services provider Illumina said Roche's $5.7 billion takeover offer was \"grossly inadequate\" and that the Swiss drug maker's director candidates should be rejected.", "section_name": "Business Day", "print_page": null, "document_type": "blogpost", "byline": {"person": [{"lastname": "DE LA MERCED", "rank": 1, "firstname": "Michael", "role": "reported", "organization": "", "middlename": "J."}], "original": "By MICHAEL J. DE LA MERCED"}, "web_url": "http://dealbook.nytimes.com/2012/02/07/illumina-formally-rejects-roches-takeover-bid/", "lead_paragraph": "Illumina formally rejected Roche Holding's hostile $5.7 billion takeover bid, arguing that the offer is \"grossly inadequate\" and undervalues the company, a provider of genetic analysis services.", "headline": {"main": "Illumina Formally Rejects Roche's Takeover Bid", "kicker": "DealBook"}, "_id": "4fd3a3688eb7c8105d8eca4f", "word_count": 420, "multimedia": [], "pub_date": "2012-02-07T17:13:49Z", "source": "The New York Times", "news_desk": null, "keywords": [{"name": "organizations", "value": "Roche Holding A G", "rank": "4"}, {"name": "organizations", "value": "Illumina Inc", "rank": "3"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": "2"}, {"name": "unknown", "value": "Illumina Inc|ILMN|NASDAQ", "rank": "5"}, {"name": "type_of_material", "value": "News", "rank": "1"}, {"name": "unknown", "value": "Roche Holding A G|RHHBY|Other OTC", "rank": "6"}], "blog": [], "subsection_name": null, "type_of_material": "Blog"}